Introduction {#s1}
============

Endothelial dysfunction is an early marker for atherosclerosis and could be detected before structural changes to the vessel wall are apparent on angiography or ultrasound [@pone.0090217-Davignon1]. Several pathological conditions can lead to impairment of endothelial function, such as hypertension, diabetes, coronary artery disease and metabolic syndrome [@pone.0090217-Widlansky1]. Examination of endothelium-dependent FMD using high-resolution ultrasonography is a widely-used noninvasive method of detecting endothelial dysfunction. It has also emerged that impaired FMD has a close correlation with the systemic nature of atherosclerosis and the future development and outcome of cardiovascular events [@pone.0090217-Davignon1], [@pone.0090217-Widlansky1], [@pone.0090217-Inaba1].

The renin angiotensin system (RAS) plays a vital role in cardiovascular disease [@pone.0090217-Davignon1], [@pone.0090217-Kawano1], [@pone.0090217-Watanabe1]. Angiotensin II receptor blockers (ARBs) inhibit the receptor of angiotensin II that stimulates the synthesis of nitric oxide (NO) and increases the levels of bradykinin to play a key role in vasodilatation and inhibition of vascular hypertrophy [@pone.0090217-Watanabe1]. ARBs also promote an elastogenic profile in the extracellular matrix of the arterial wall by increasing elastin and decreasing the levels of matrix metalloproteinases. Similar mechanisms involved in regulating on RAS activity, ARBs and angiotensin-converting enzyme inhibitors (ACEIs) are both recommended first-line drugs for hypertension by guidelines [@pone.0090217-Mancia1], [@pone.0090217-James1]. A prior meta-analysis [@pone.0090217-Shahin1] pooled that ACEIs could improve endothelial function in patients with endothelial dysfunction caused by various conditions. Whether ARBs are protective on endothelial function or superior to other antihypertensives reminds unclear.

Over the last decades, intensive research has investigated the potential clinical benefits of ARBs. Several clinical trials [@pone.0090217-Koh1], [@pone.0090217-Sola1], [@pone.0090217-Rajagopalan1], [@pone.0090217-Warnholtz1], [@pone.0090217-PerroneFilardi1], [@pone.0090217-Pelliccia1], [@pone.0090217-Koh2], [@pone.0090217-Lunder1], [@pone.0090217-Ghiadoni1], [@pone.0090217-Trevelyan1], [@pone.0090217-SouzaBarbosa1], [@pone.0090217-Hornig1], [@pone.0090217-Yavuz1], [@pone.0090217-Koh3], [@pone.0090217-Sozen1], [@pone.0090217-Morimoto1], [@pone.0090217-Benndorf1], [@pone.0090217-Yilmaz1], [@pone.0090217-Wei1], [@pone.0090217-Takiguchi1], [@pone.0090217-Flammer1], [@pone.0090217-Chung1] have tested the effect of ARBs on endothelial dysfunction using forearm FMD (brachial or radial artery) in patients with endothelial dysfunction caused by different pathological lesions. In this meta-analysis we investigated the ARBs compared with placebo or no treatment or other antihypertensives (ACEIs, CCBs, β-blockers, diuretics) on peripheral endothelial function as measured by FMD in patients with endothelial dysfunction.

Materials and Methods {#s2}
=====================

Search strategy {#s2a}
---------------

Studies were eligible to be included in our meta-analysis if they were: (1) randomized controlled trials which compared any kinds of ARBs with monotherapy of placebo or no treatment or with other anti-hypertensives (ACEIs, CCBs, β-blockers or diuretics); (2) included patients with endothelial dysfunction (hypertension, type 2 diabetes, coronary artery disease, chronic kidney disease or elderly) as either the study population or a subgroup; (3) Used forearm FMD (Flow mediated vasodilatation or Flow mediated dilatation or Flow mediated dilation) measured by high-resolution ultrasound to assess peripheral endothelial function; (3) Minimum period of treatment with ARBs is more than 4 weeks or 1 month; (4) articles published in English until to September 2013.

Data extraction {#s2b}
---------------

The following data were recorded for each study: first author, year of publication, country of research, number of participants randomized to ARBs and controls (not the total number that participated in the RCTs), age and gender, number of participants randomized into ARBs, placebo or no treatment and other antihypertensives respectively, ARBs type and dose, duration of treatment, controls type and dose, FMD at baseline and at the end of the study period, outcome. Authors of included studies were contacted when data was not available as appropriate (2 crossover trials as missing baseline FMD and 1 parallel double-blind trial as missing FMD change value). 2 independent reviewers (Shuang Li and Yan Wu) extracted and checked the data separately. Disagreements were resolved by consensus with the third reviewer, prof. Yawei Xu.

Assessment of methodological quality {#s2c}
------------------------------------

Two reviewers (Shuang Li and Yan Wu) assessed the methodological quality assessment independently and any incongruity was discussed and resolved. The methodological quality of the included studies was assessed by the elements of the Cochrane collaboration tool, by which the risk of bias in each trial was assessed [@pone.0090217-SouzaBarbosa1]. A total of 7 domains were reported for each study including: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, follow-up, selective reporting and other bias. Jadad scoring system was adopted in the same time.

Statistical methods for the meta-analysis {#s2d}
-----------------------------------------

A random-effect model was obtained to conduct a meta-analysis of all the relevant RCTs to get a conservative conclusion. For continuous variables, weighted mean difference (WMD) was measured along with 95% CI, which is a measure of the likelihood of chance effects leading to random errors. A P value \<0.05 was considered significant. The inter study heterogeneity was examined by both chi-squared test and I^2^ statistics. The heterogeneity was considered statistically significant when P\<0.1 or I^2^\>50%. Potential publication bias was assessed by both visual evaluation of funnel plot and Egger\'s test. The STATA (version 11.0; StataCorp) were used to conduct this meta-analysis. We also used meta-regression to test for a duration--effect relationship between duration of ARBs treatment and the change percent of FMD.

To explore the source of heterogeneity, each included study was removed one by one to detect its contribution on the heterogeneity. Besides, the meta-regression was also conducted to evaluate the source of heterogeneity. The sensitivity analysis was conducted excluding each study one at a time and then detecting the efficiency of ARBs on the FMD. The results would be considered robust when the results didn\'t change significantly.

Results {#s3}
=======

1 Literature searching {#s3a}
----------------------

The searching protocol identified 1594 potentially eligible studies of which 281 were duplicated and 1230 studies were excluded on title and abstract. Full articles of the remaining 62 studies were collected and evaluated. 22 studies [@pone.0090217-Koh1]--[@pone.0090217-Chung1] met our inclusion criteria and were included in the meta-analysis.(see [Fig.1](#pone-0090217-g001){ref-type="fig"}) We classified included trials into two groups: 11 trials compared ARBs with placebo [@pone.0090217-Koh1]--[@pone.0090217-Lunder1] or no treatment [@pone.0090217-Ghiadoni1], [@pone.0090217-Trevelyan1], [@pone.0090217-SouzaBarbosa1], 16 trials [@pone.0090217-Koh2]--[@pone.0090217-Chung1] compared ARBs with other antihypertensives [@pone.0090217-Koh2], [@pone.0090217-Ghiadoni1]--[@pone.0090217-Chung1] (with ACEI in 8 trials [@pone.0090217-Lunder1]--[@pone.0090217-Sozen1], CCBs in 7 trials [@pone.0090217-Koh2], [@pone.0090217-Ghiadoni1], [@pone.0090217-Morimoto1]--[@pone.0090217-Takiguchi1] β-blockers in 3 trials [@pone.0090217-Koh2], [@pone.0090217-Ghiadoni1], [@pone.0090217-Flammer1], diuretics in 3 trials [@pone.0090217-Koh2], [@pone.0090217-SouzaBarbosa1], [@pone.0090217-Chung1]). 21 studies detected brachial FMD and 1 study detected radial FMD [@pone.0090217-Hornig1].

![Study flow diagram and exclusion criteria.\
The searching protocol identified 1594 potentially eligible studies of which 281 were duplicated and 1230 studies were excluded on title and abstract. Full articles of the remaining 62 studies were collected and evaluated. 22 studies met our inclusion criteria and were included in the meta-analysis.](pone.0090217.g001){#pone-0090217-g001}

2 Characteristics of patients and trials {#s3b}
----------------------------------------

Our meta-analysis included 1737 patients of 11 countries and 22 trials totally ([Table 1](#pone-0090217-t001){ref-type="table"}). In all trials, major characteristics of patients at baseline were similar between study groups. The mean age of patients ranged from 40 [@pone.0090217-Yavuz1] to 71 [@pone.0090217-Rajagopalan1] years old. 2 studies assessed ARBs effect on brachial FMD in male only [@pone.0090217-Lunder1], [@pone.0090217-Trevelyan1]. The mean systolic blood pressure ranged from 123 to 162.8 mmHg and the diastolic blood pressure ranged from 70 [@pone.0090217-Rajagopalan1] to 100 mmHg [@pone.0090217-Koh1], [@pone.0090217-Ghiadoni1] at baseline. Mean follow-up duration ranged from 4 weeks [@pone.0090217-Sola1], [@pone.0090217-Pelliccia1], [@pone.0090217-Hornig1], [@pone.0090217-Flammer1] to 3 years [@pone.0090217-Sozen1]. Patients\' characteristics are summarized in [Table 2](#pone-0090217-t002){ref-type="table"}.

10.1371/journal.pone.0090217.t001

###### Characteristics of included trials.

![](pone.0090217.t001){#pone-0090217-t001-1}

  First author, Year \[Ref \#\]                                                Country      Protocol    Participants (n)   ARBs (n)                      ARBs Dose/Day                      Duration   Control (n)               Control Dose/Day                                                     Outcome
  ------------------------------------------------------------------------- ------------- ------------ ------------------ ---------- ----------------------------------------------------- ---------- ------------- ------------------------------------------ -------------------------------------------------------------------------------------
  ***ARBs vs. placebo or no treatment***                                                                                                                                                                                                                       
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                     Italy        R,P,SB            69             29                    telmisartan,80--160 mg                    6 m          40                      no treatment                                                  No effect on FMD
  K.K.Koh,2004 [@pone.0090217-Koh1]                                             Korea       R,DB,PC           122             92      Losartan,100 mg/irbesartan,300 mg/candesartan,16 mg     2 m          30                        placebo                                                       Improved FMD
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1]                                    UK           R,DB             33             18                        losartan,50 mg                        5 m          15                      no treatment                                                    Improved FMD
  S.Sola,2005 [@pone.0090217-Sola1]                                              USA        R,DB,PC            28             14                       Irbesartan,150 mg                      4 w          14                        placebo                                                       Improved FMD
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                         Brazil       R,O,P,PC           39             14                       Irbesartan,150 mg                      12 w         25                      no treatment                                                    Improved FMD
  S.Rajagopalan,2006 [@pone.0090217-Rajagopalan1]                                USA       R,DB,PC,CO          33             33                     Valsartan,160--320 mg                    26 w         33                        placebo                                                       Improved FMD
  A.Warnholtz,2007 [@pone.0090217-Warnholtz1]                                  Germany      R,DB,PC            63             30                       Irbesartan,300 mg                      6 m          33                        placebo                                                       Improved FMD
  P.P.Filardi,2009 [@pone.0090217-PerroneFilardi1]                              Italy       R,DB,PC            26             13                       Candesartan,16 mg                      2 m          13                        placebo                                                       Improved FMD
  F.Pelliccia,2010 [@pone.0090217-Pelliccia1]                                   Italy      R,DB,P,PC           40             20                      Telmisartan,160 mg                      4 w          20                        placebo                                                       Improved FMD
  K.K.Koh,2010 [@pone.0090217-Koh2]                                             Korea      R,SB,PC,P           62             31                       Candesartan,16 mg                      8 w          31                        placebo                                                       Improved FMD
  M.Lunder,2011 [@pone.0090217-Lunder1]                                       Slovenia      R,DB,PC            40             20                        Valsartan,20 mg                       30 d         20                        placebo                                                       Improved FMD
  ***ARBs vs. other antihypertensives (ACEI, CCB, β-blocker, diuretic)***                                                                                                                                                                                      
  ***1. ARB vs. ACEI***                                                                                                                                                                                                                                        
  B.Hornig,2001 [@pone.0090217-Hornig1]                                        Germany         R               35             17                        losartan,100 mg                       4 w          18                     ramipril,10 mg                                        FMD improved under both treatments
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                     Italy        R,SB,P            57             29                      telmisartan,160 mg                      6 m          28                    Perindopril,4 mg                                          FMD improved only under ACEI
  D.Yavuz,2003 [@pone.0090217-Yavuz1]                                          Turkey        R,O,P             18             9                         Losartan,100 mg                       6 m           9                    Enalapril,40 mg                                        FMD improved under both treatments
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1]                                    UK           R,DB             34             18                        losartan,50 mg                        5 m          16                    enalapril,10 mg                                        FMD improved under both treatments
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                         Brazil        R,O,PC            30             14                       irbesartan,150 mg                      12 w         16                    Quinapril,20 mg                                        FMD improved under both treatments
  K.K.Koh,2007 [@pone.0090217-Koh3]                                             Korea      R,DB,CO,PC          34             34                       candesartan,16 mg                      4 m          34                     ramipril,10 mg                                        FMD improved under both treatments
  A.B.SOZEN,2009 [@pone.0090217-Sozen1]                                        Turkey          R               44             22              Irbesartan,300 mg/valsartan,160 mg              36 m         22            Fosinopril,10 mg/quinapril,20 mg       FMD improved under both treatments at the start of the trial but was not maintained
  K.K.Koh,2010 [@pone.0090217-Lunder1]                                          Korea      R,SB,PC,P           61             31                       Candesartan,16 mg                      8 w          30                     ramipril,10 mg                                        FMD improved under both treatments
  ***2. ARB vs. CCB***                                                                                                                                                                                                                                         
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                     Italy         R,P              85             29                    Telmisartan,80--160 mg                    6 m          56        nifedipine,30--60 mg/amlodipine,5--10 mg                                No effect on FMD either.
  S.Morimoto,2006 [@pone.0090217-Morimoto1]                                     Japan          R               43             21                       Telmisartan,40 mg                      24 w         22                    amlodipine,5 mg                                             ARB improved FMD than CCB
  R.A.Benndorf,2007 [@pone.0090217-Benndorf1]                                  Germany       R,SB,P            25             12                     Telmisartan,40--80 mg                    6 w          13                 Nisoldipine,10--20 mg                                          ARB improved FMD than CCB
  K.K.Koh,2010 [@pone.0090217-Koh2]                                             Korea      R,SB,PC,P           61             31                       Candesartan,16 mg                      8 w          30                    Amlodipine,10 mg                                            ARB improved FMD than CCB
  M.I.Yilmaz,2010 [@pone.0090217-Yilmaz1]                                      Turkey          R               72             37                       Valsartan,160 mg                       12 w         35                    amlodipine,10 mg                                       FMD improved under both treatments
  D.Wei,2011 [@pone.0090217-Wei1]                                               China        R,P,SB            55             27                       olmesartan,20 mg                       8 w          27                   nisoldipine,10 mg                                       FMD improved under both treatments
  S.Takiguchi,2011 [@pone.0090217-Takiguchi1]                                   Japan         R,CO             31             15                       olmesartan,40 mg                       12 w         16                    amlodipine,10 mg                                            ARB improved FMD than CCB
  ***3. ARB vs. β-blocker***                                                                                                                                                                                                                                   
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                     Italy         R,P              86             29                    telmisartan,80--160 mg                    6 m          57         atenolol,50--100 mg/nebivolol,5--10 mg                                 No effect on FMD either.
  A.J. Flammer,2007 [@pone.0090217-Flammer1]                                 Switzerland    R,DB,CO            14             14                        losartan,100 mg                       4 w          14                    atenolol,100 mg                                          ARB improved FMD than β-blocker
  K.K.Koh,2010 [@pone.0090217-Koh2]                                             Korea      R,SB,PC,P           62             31                       candesartan,16 mg                      8 w          31                    atenolol,100 mg                                          ARB improved FMD than β-blocker
  ***4. ARB vs. diuretics***                                                                                                                                                                                                                                   
  N.A.Chung,2004 [@pone.0090217-Chung1]                                          UK          R,DB,             40             21                      losartan,50--100 mg                     12 w         19            hydrochlorothiazide,12.5--25 mg                                  ARB improved FMD than diuretics
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                         Brazil        R,O,PC            32             14                       irbesartan,150 mg                      12 w         18               hydrochlorothiazide,20 mg                                   FMD improved under both treatments
  K.K.Koh,2010 [@pone.0090217-Koh2]                                             Korea      R,SB,PC,P           62             31                       candesartan,16 mg                      8 w          31               hydrochlorothiazide,50 mg                                     ARB improved FMD than diuretics

FMD flow mediated dilatation; O open; P parallel; CO crossover; PC placebo-control; DB double-blind; SB single-blind; R randomized; ARB angiotensin receptor blocker; ACEI angiotensin-converting enzyme inhibitors; CCB calcium channel blocker; NR not reported; m month; w week; d day.

10.1371/journal.pone.0090217.t002

###### Characteristics of participants.

![](pone.0090217.t002){#pone-0090217-t002-2}

  First author, Year(Ref \#)                                                                                       Participants                         Mean Age   Male/Female   Mean SBP mmHg   Mean DBP mmHg   Smokers n (%)   Diabetes mellitus n%
  ----------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------- ------------- --------------- --------------- --------------- ----------------------
  ***ARBs vs. placebo or no treatment***                                                                                                                                                                                        
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                                  essential hypertension;                      49.8        42/27          132.4           87.1             NR                  NR
  K.K.Koh,2004 [@pone.0090217-Koh1]                                                                       mild-to-moderate hypertension                   48.5        96/26          162.8            100              0                  0
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1]                                                                stable CAD awaiting CABG                     63.2        33/0            140             82               0                3(9.1)
  S.Sola,2005 [@pone.0090217-Sola1]                                                                             metabolic syndrome                        41.5        12/16           133            77.5             NR                  NR
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                                             hypertension                           47.9        17/22          138.9           83.5             NR                  NR
  S.Rajagopalan,2006 [@pone.0090217-Rajagopalan1]                                                          healthy normotensive elders                     71         21/14           123             70              NR                  NR
  A.Warnholtz,2007 [@pone.0090217-Warnholtz1]                                                                       stable CAD                             60         63/19           NR              NR           24(29.3)            11(13.4)
  P.P.Filardi,2009 [@pone.0090217-PerroneFilardi1]                                                         hypertension with stable CAD                    58         27/1            123             78           25(89.2)               NR
  F.Pelliccia,2010 [@pone.0090217-Pelliccia1]                                                             normotensive patients with CAD                   57         27/13           133             86              NR               9(22.5)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                                                hypertension                           46.5        43/19           154            93.5             NR                  0
  M.Lunder,2011 [@pone.0090217-Lunder1]                                                                              healthy                               43         40/0            123             75               0                  0
  ***ARBs vs. other antihypertensives (ACEI, CCB, β-blocker, diuretic) 1. ARB vs. ACEI***                                                                                                                                       
  B.Hornig,2001 [@pone.0090217-Hornig1]                                                                                CAD                                59.5         NR             NR              NR              NR                  NR
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                                        hypertension                           50.5        36/21           152             100             NR                  NR
  D.Yavuz,2003 [@pone.0090217-Yavuz1]                                                                              hypertension                            40          9/9            149             98               0                  0
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1]                                                                stable CAD awaiting CABG                     63.8        34/0            143            81.6           2(5.9)              3(8.8)
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                                             hypertension                           49.5        13/17          158.4           92.1             NR                  NR
  K.K.Koh,2007 [@pone.0090217-Koh3]                                                                                hypertension                            46         23/11          155.5            95            11(32)                0
  A.B.SOZEN,2009 [@pone.0090217-Sozen1]                                                                   mild-to-moderate hypertension                    45         18/24           NR              NR           12(27.3)            20(45.5)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                                                hypertension                           46.5        42/19           155             94              NR                  NR
  ***2. ARB vs. CCB***                                                                                                                                                                                                          
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                  essential hypertension; normotensive subjects as control     51.6        52/33           152             100             NR                  NR
  S.Morimoto,2006 [@pone.0090217-Yavuz1]                                                                 untreated hypertensive patients                   57         18/25          162.5            94           11(25.6)               NR
  R.A.Benndorf,2007 [@pone.0090217-Benndorf1]                                                                 essential hypertension                      57.9        13/12           NR              NR             1(4%)                NR
  M.I.Yilmaz,2010 [@pone.0090217-Yilmaz1]                                                        diabetic CKD stage I patients with hypertension           47         33/39           149             91              NR               72(100%)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                                                hypertension                            49         41/20          155.5            95              NR                  NR
  D.Wei,2011 [@pone.0090217-Wei1]                                                                                  hypertension                           58.6        41/14           148            87.8             NR                  NR
  S.Takiguchi,2011 [@pone.0090217-Takiguchi1]                                                                 essential hypertension                       56         27/4           150.5           92.9          10(32.2)            7(22.6)
  ***3.ARB vs. β-blocker***                                                                                                                                                                                                     
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                                        hypertension                            52         53/33           153             99              NR                  NR
  A.J. Flammer,2007 [@pone.0090217-Flammer1]                                                             type 2 diabetes and hypertension                 61.3        10/3            133             82            6(46.2)            13(100)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                                                hypertension                            48         43/19           156             95              NR                  NR
  ***4.ARB vs. diuretics***                                                                                                                                                                                                     
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                                                hypertension                           47.5        42/20          154.5            94              NR                  NR
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                                             hypertension                           49.8        13/19          156.8           91.1             NR                  NR
  N.A.Chung,2004 [@pone.0090217-Chung1]                                                                            hypertension                           55.9        28/12           161             95            10(25)              4(10)

3 The methodological quality of the included trials {#s3c}
---------------------------------------------------

The methodological quality of the included studies ranged from poor to moderate, with a median Jadad score of 3, range (1--3). This resulted from poor description of randomization and allocation concealment methods and the lack of double-blinding. Three studies [@pone.0090217-Ghiadoni1], [@pone.0090217-SouzaBarbosa1], [@pone.0090217-Sozen1] lacked adequate reporting on loss to follow up and withdrawals. In 2 studies [@pone.0090217-Pelliccia1], [@pone.0090217-Chung1], diuretics were added to study treatments to normalize blood pressure in patients remaining hypertensive in spite of being on study treatments which might have affected the results too. Two studies [@pone.0090217-Lunder1], [@pone.0090217-Trevelyan1] included males only which might result in selective bias. Other aspects of methodological quality of the included trials are summarized in [Table 3](#pone-0090217-t003){ref-type="table"}.

10.1371/journal.pone.0090217.t003

###### Risk of bias assessment.

![](pone.0090217.t003){#pone-0090217-t003-3}

  First author, Year(Ref \#)                                                Adequate sequence generation   Allocation concealment   Blinding (observer)   Blinding (patient)   Adequate report on loss to follow-up     Free of other sourced of bias      Jadad score
  ------------------------------------------------------------------------ ------------------------------ ------------------------ --------------------- -------------------- -------------------------------------- ------------------------------------ -------------
  ***ARBs vs. placebo or no treatment***                                                                                                                                                                                                                  
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                             Yes                          NR                     Yes                   NO                            NO                    NO[a](#nt102){ref-type="table-fn"}        1
  K.K.Koh,2004 [@pone.0090217-Koh1]                                                     Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1]                                           Yes                          NR                     Yes                   NO                           Yes                    NO[b](#nt103){ref-type="table-fn"}        3
  S.Sola,2005 [@pone.0090217-Sola1]                                                     Yes                         Yes                     Yes                  Yes                           Yes                                    NO                        3
  L.A.Souza-Barbosa,2006 [@pone.0090217-Ghiadoni1]                                      Yes                          NO                     NO                    NO                            NO                                   Yes                        2
  S.Rajagopalan,2006 [@pone.0090217-Rajagopalan1]                                       Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  A.Warnholtz,2007 [@pone.0090217-Warnholtz1]                                           Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  P.P.Filardi,2009 [@pone.0090217-PerroneFilardi1]                                      Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  F.Pelliccia,2010 [@pone.0090217-Pelliccia1]                                           Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                     Yes                         Yes                     NO                   Yes                           Yes                                   Yes                        3
  M.Lunder,2011 [@pone.0090217-Lunder1]                                                 Yes                          NR                     Yes                  Yes                           Yes                    NO[b](#nt103){ref-type="table-fn"}        3
  ***ARBs vs. other antihypertensives(ACEI, CCB, β-blocker, diuretic)***                                                                                                                                                                                  
  B.Hornig,2001 [@pone.0090217-Hornig1]                                                 Yes                          NR                     NO                    NO                           Yes                                    NO                        1
  D.Yavuz,2003 [@pone.0090217-Yavuz1]                                                   Yes                          NO                     NO                    NO                           Yes                                   Yes                        2
  K.K.Koh,2007 [@pone.0090217-Koh3]                                                     Yes                          NR                     Yes                  Yes                           Yes                                   Yes                        3
  A.B.SOZEN,2009 [@pone.0090217-Sozen1]                                                 Yes                          NO                     NO                    NO                            NO                                    NO                        1
  S.Morimoto,2006 [@pone.0090217-Morimoto1]                                             Yes                          NO                     NR                    NR                            NR                                    NO                        1
  R.A.Benndorf,2007 [@pone.0090217-Benndorf1]                                           Yes                          NR                     NO                   Yes                            NR                                    NO                        2
  M.I.Yilmaz,2010 [@pone.0090217-Yilmaz1]                                               Yes                          NR                     NR                    NR                            NR                                    NO                        1
  D.Wei,2011 [@pone.0090217-Wei1]                                                       Yes                          NR                     NO                   Yes                           Yes                                    NO                        2
  S.Takiguchi,2011 [@pone.0090217-Takiguchi1]                                           Yes                          NO                     NO                    NO                           Yes                                    NO                        1
  A.J. Flammer,2007 [@pone.0090217-Flammer1]                                            Yes                          NR                     Yes                  Yes                           Yes                                    NO                        3
  N.A.Chung,2004 [@pone.0090217-Chung1]                                                 Yes                          NR                     Yes                  Yes                           Yes                    NO[a](#nt102){ref-type="table-fn"}        3

A diuretic was added to study treatments to normalize blood pressure.

Included men only.

**NR** not reported; **ARB** Angiotensin receptor blocker; **ACEI** Angiotensin-converting enzyme inhibitors; **CCB** Calcium channel blocker.

4 FMD measurement {#s3d}
-----------------

There was certain variation in the values of FMD among included studies. FMD change percent ranged from -0.3% [@pone.0090217-Rajagopalan1] to 2% [@pone.0090217-SouzaBarbosa1] in the placebo or no treatment group and 0.3% [@pone.0090217-Ghiadoni1] to 5.9% [@pone.0090217-SouzaBarbosa1] in relative ARBs groups. Also, when compared between ARBs with other antihypertensives, FMD ranged from −3.8% [@pone.0090217-Sozen1] to 5.6% [@pone.0090217-Yavuz1] and −3.95% [@pone.0090217-Sozen1] to 5.9% [@pone.0090217-SouzaBarbosa1] in relative ARBs groups. Other aspects of FMD measurements across included studies are summarized in [Table 4](#pone-0090217-t004){ref-type="table"}.

10.1371/journal.pone.0090217.t004

###### Technical aspects of forearm FMD measurement.

![](pone.0090217.t004){#pone-0090217-t004-4}

  First author, Year(Ref \#)                                                                 Mean change FMD (SD)   Probe (device) MHz        Position           Reproducibility     
  ----------------------------------------------------------------------------------------- ---------------------- -------------------- -------------------- ----------------------- -------------------------------------------------------------------------------------------------------------------------
  ***ARBs vs. placebo or no treatment***                                                                                                                                             
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                        0.3±2.9               0.1±1.06                NR              brachial artery                                                                NR
  K.K.Koh,2004 [@pone.0090217-Koh1]                                                               1.36±0.364            0.15±0.26           10(Bothell)       right brachial artery                                                             NR
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1],2m                                                   0.6±0.60              0.3±0.51             5-10(GE)           brachial artery                                                                NR
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1],5m                                                   3.3±0.65              2.0±0.68             5-10(GE)           brachial artery                                                                NR
  S.Sola,2005 [@pone.0090217-Sola1]                                                                2.7±0.82              0.2±0.98                NR              brachial artery                              the average value was determined from at least 3 different measurements
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                             5.9±2.81               2±2.23           7-12(ALT HDI)         brachial artery                              Mean difference between measures (0.9%); Intraobserver variability\<2%
  S.Rajagopalan,2006 [@pone.0090217-Rajagopalan1]                                                  0.8±0.9               −0.3±0.8              10(NR)            brachial artery                                                                NR
  A.Warnholtz,2007 [@pone.0090217-Warnholtz1]                                                       2±0.65               0.3±0.56                NR              brachial artery                                                  correlation coefficient (0.99)
  P.P.Filardi,2009 [@pone.0090217-PerroneFilardi1]                                                 1.88±2.3             1.39±2.15             7.5 (NR)           brachial artery                                                                NR
  F.Pelliccia,2010 [@pone.0090217-Pelliccia1]                                                      4.9±3.5               0.6±3.2         7.5--12.5(Vivid 7)   right brachial artery   variability (0.38±0.26%);coefficient of variation(1.26%);coefficient of repeatability(0.5%) variability (0.01--0.02 mm)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                               1.62±0.29             0.62±0.26             10(ATL)         right brachial artery                      Interobserver variability (0.07--1.27%); Intraobserver variability (0.15--1.24%)
  M.Lunder,2011 [@pone.0090217-Lunder1]                                                            2.7±0.37              0.3±0.27          NR(Aloka alfa)     right brachial artery                                                             NR
  ***ARBs vs. other antihypertensives (ACEI, CCB, β-blocker, diuretic) 1. ARB vs. ACEI***                                                                                            
  B.Hornig,2001 [@pone.0090217-Hornig1]                                                            0.12±0.1              0.12±0.1            10(ASULAB)           radial artery                                                                 NR
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                        0.3±2.9               1.5±2.1             7(ESAOTE)           bradial artery                              Intraobserver variability (14%); Mean difference between measures (0.9%)
  D.Yavuz,2003 [@pone.0090217-Yavuz1]                                                              4.5±3.06              5.6±4.25          8.5(Logic 700)        bradial artery                              Mean difference between measures (0.9%);Intraobserver variability (1--3%)
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1],2m                                                   0.6±0.60              0.7±0.49             5-10(GE)           brachial artery                                                                NR
  J.Trevelyan,2005 [@pone.0090217-Trevelyan1],5m                                                   3.3±0.65              3.9±0.56             5-10(GE)           brachial artery                                                                NR
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                             5.9±2.81               6±2.48           7--12(ALT HDI)        bradial artery                               Mean difference between measures (0.9%); Intraobserver variability\<2%
  K.K.Koh,2007 [@pone.0090217-Koh3]                                                               1.58±1.71              1.7±1.75             10(ATL)            brachial artery                                                                NR
  A.B.SOZEN,2009 [@pone.0090217-Sozen1]                                                            −3.95±5               −3.8±4.6           10(VingMed)          brachial artery                                            Intra-andinter-observer variabilities 1--3%
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                               1.62±0.29             1.66±0.31             10(ATL)         right brachial artery                      Interobserver variability (0.07--1.27%); Intraobserver variability (0.15--1.24%)
  ***2. ARB vs. CCB***                                                                                                                                                               
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                        0.3±2.9              −0.4±2.45            7(ESAOTE)           brachial artery                             Intraobserver variability (14%); Mean difference between measures (0.9%)
  S.Morimoto,2006 [@pone.0090217-Morimoto1]                                                         3±0.92              −0.9±0.82             7.5(GE)            brachial artery                                                                NR
  R.A.Benndorf,2007 [@pone.0090217-Benndorf1]                                                     5.44±4.19             −0.68±3.57            12(ATL)            brachial artery                                              Mean intraindividual coefficient (4.2%)
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                               1.62±0.29             1.22±0.29             10(ATL)         right brachial artery                      Interobserver variability (0.07--1.27%); Intraobserver variability (0.15--1.24%)
  M.I.Yilmaz,2010 [@pone.0090217-Yilmaz1]                                                         1.2±0.747            0.375±0.954          12(Bethell)          brachial artery                                                                NR
  D.Wei,2011 [@pone.0090217-Wei1]                                                                 2.91±4.48               4±7.06            7.5(Philips)         brachial artery                        The variability was 12% with a mean difference of 0.8% between the two measurements
  S.Takiguchi,2011 [@pone.0090217-Takiguchi1]                                                     1.59±2.92             0.04±2.34            7.5(Aplio)       right brachial artery                                      The intra- and inter-observer variability (\<3%)
  ***3. ARB vs. β-blocker***                                                                                                                                                         
  L.Ghiadoni,2003 [@pone.0090217-Ghiadoni1]                                                        0.3±2.9               0.4±2.15            7(ESAOTE)           brachial artery                              Intraobserver variability (14%) Mean difference between measures (0.9%)
  A.J.Flammer,2007 [@pone.0090217-Flammer1]                                                       0.73±0.43             −0.11±0.45           10(WTS-2)           brachial artery                                                                NR
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                               1.62±0.29              0.8±0.35             10(ATL)         right brachial artery                      Interobserver variability (0.07--1.27%); Intraobserver variability (0.15--1.24%)
  ***4. ARB vs. diuretics***                                                                                                                                                         
  N.A.Chung,2004 [@pone.0090217-Chung1]                                                            1.15±4.6            −0.26±4.571             10(GE)            brachial artery                                                                NR
  L.A.Souza-Barbosa,2006 [@pone.0090217-SouzaBarbosa1]                                             5.9±2.81             5.5±2.722          7--12(ALT HDI)        brachial artery                               Mean difference between measures (0.9%);Intraobserver variability\<2%
  K.K.Koh,2010 [@pone.0090217-Koh2]                                                               1.62±0.29             0.71±0.24             10(ATL)         right brachial artery                      Interobserver variability (0.07--1.27%); Intraobserver variability (0.15--1.24%)

5 Outcome measures reporting {#s3e}
----------------------------

### 5.1 ARBs versus placebo or no treatment {#s3e1}

Overall, 11 trials [@pone.0090217-Koh1]--[@pone.0090217-SouzaBarbosa1] assessed the effect of ARBs on FMD compared to placebo or no treatment, all using brachial arteries. These studies included 590 patients of which 315 patients received ARBs and 275 patients received placebo (8 trials [@pone.0090217-Koh1]--[@pone.0090217-Lunder1]) or no treatment (3 trials [@pone.0090217-Ghiadoni1], [@pone.0090217-Trevelyan1], [@pone.0090217-SouzaBarbosa1]). Across the 11 trials we found significant heterogeneity (I^2^ = 94.3%, p\<0.00001). A random effect model showed that treatment with ARBs significantly improved brachial FMD (pooled mean change difference  = 1.36%) (see [Fig. 2](#pone-0090217-g002){ref-type="fig"}).

![Forest plot illustrating ARBs effect on brachial FMD change compared with placebo or no treatment.\
In 11 trials including 590 patients, ARBs (n = 315) significantly improved FMD (1.36%, 95% CI: 1.28 to 1.44) versus placebo or no treatment (n = 275).](pone.0090217.g002){#pone-0090217-g002}

### 5.2 ARBs versus other antihypertensives {#s3e2}

In 15 trials (14 using brachial FMD and 1 using radial FMD [@pone.0090217-Hornig1]) which included 1028 patients, treatment with ARBs (n = 486) had a significant effect on FMD when compared with other antihypertensives (ACEI, CCBs, β-blockers and diuretics) (n = 542) (pooled mean change difference 0.59%, 95% CI 0.25--0.94, I^2^ = 95.7%, p for heterogeneity \<0.00001) (see [Fig. 3](#pone-0090217-g003){ref-type="fig"}).

![Forest plot illustrating ARBs effect on changes in FMD compared with other antihypertensive agents (ACEI, CCB, β-blockers and diuretics).\
In 16 trials that included 1028 patients, ARBs (n = 486) had a significant effect (0.59%, 95% CI: 0.25 to 0.94) on FMD when compared with other antihypertensives (n = 542). In 8 trials, ARBs (n = 174) had no significant effect (−0.14%, 95% CI: −0.32 to 0.03) compared with ACEI (n = 173). Compared with others, the benefits of ARBs respectively were 1.67% (95% CI: 0.65 to 0.93) in 7 trials with CCBs, 0.79% (95% CI: 0.42 to 1.01) with β-blockers in 3 trials and 0.9% (95% CI: 0.77 to 1.03) with diuretics in 3 trials.](pone.0090217.g003){#pone-0090217-g003}

### 5.3 ARBs versus ACEI {#s3e3}

In 8 trials (7 with brachial FMD and 1 with radial FMD [@pone.0090217-Hornig1]), treatment with ARBs (n = 174) had no significant effect on FMD when compared with ACEI (n = 173) (pooled mean change difference  = −0.14%, 95% CI 0.32 to 0.03, p = 0.082, I^2^  = 37.52%).

### 5.4 ARBs versus CCB {#s3e4}

In 7 trials [@pone.0090217-Koh2], [@pone.0090217-Ghiadoni1], [@pone.0090217-Morimoto1]--[@pone.0090217-Takiguchi1], all using brachial FMD, ARBs (n = 172) significantly improved FMD when compared with CCBs (n = 199) (pooled mean change difference 1.67%, 95% CI 0.65--0.93, I^2^ = 96.6%, p for heterogeneity \<0.00001).

### 5.5 ARBs versus β-blockers {#s3e5}

When compared with β-blockers in 3 trials [@pone.0090217-Koh2], [@pone.0090217-Ghiadoni1], [@pone.0090217-Flammer1], all using brachial FMD, ARBs also had a significant effect on FMD (pooled mean change difference  = 0.79%, 95% CI 0.42--1.01, I^2^ = 0%, p for heterogeneity  = 0.427).

### 5.6 ARBs versus diuretics {#s3e6}

Three trials [@pone.0090217-Koh2], [@pone.0090217-SouzaBarbosa1], [@pone.0090217-Chung1] which included 134 patients evaluated the effect of ARBs versus diuretics on FMD, all using brachial arteries, ARBs also had a significant effect on FMD (pooled mean change difference  = 0.9%, 95% CI 0.77--1.03, I^2^ = 0%, p for heterogeneity  =  0.808).

### 5.7 Duration-effect relationship {#s3e7}

We also analyze the relationship between the FMD change and the duration of ARBs treatments using meta-regression. In available 25 values of total 22 studies (J. Trevelyan [@pone.0090217-Trevelyan1] has 2 values of different time-points, A.B.SOZEN [@pone.0090217-Sozen1] has 3 values), of which 21 have results with follow-up less than or equal to 6 months and 2 trials [@pone.0090217-Rajagopalan1], [@pone.0090217-Sozen1] contributed data more than 6 months. We found that the FMD change percent was relatively stable in the first 6 months (95% CI −0.484 to 0.360, p = 0.764) (see [Fig.4](#pone-0090217-g004){ref-type="fig"}), but felt down quickly after 6 month (95% CI-1.065 to 0.549, p = 0.154). In total, the benefit of ARBs on endothelial function wouldn\'t be well maintained (95% CI −1.990 to −0.622, p = 0.001) (see [Fig. 4](#pone-0090217-g004){ref-type="fig"}).

![Relationship between the FMD change and the duration of ARBs treatments included all 22 trials.\
In available 25 values of total 22 studies, FMD change percent was relatively stable in the first 6 months (95% CI −0.484 to 0.360, p = 0.764), but felt down quickly after 6 month (95% CI−1.065 to 0.549, p = 0.154). In total, the benefit of ARBs on endothelial function wouldn\'t be well maintained (95% CI −1.990 to −0.622, p = 0.001).](pone.0090217.g004){#pone-0090217-g004}

6 Publication bias {#s3f}
------------------

We found no significant evidence for publication bias. The Begg\'s test (P = 0.350) and the Egger\'s test (P = 0.357) also provided no statistical evidence for publication bias.

Discussion {#s4}
==========

Major findings {#s4a}
--------------

Our study is important in the sense that this is the first meta-analysis in the literature which assesses the effect of ARBs on peripheral endothelial function compared to placebo or no treatment and other antihypertensives. One of main findings of our meta-analysis is that treatments with ARBs could improve peripheral endothelial function compared with placebo or no treatment for patients who are suffering from endothelial dysfunction. When compared to other antihypertensives, ARBs show priority to CCBs, β-blockers and diuretics but have no significant difference with ACEI. Interestingly, although the anti-hypertensive targets of included RCTs have been well reached, we found the effect of ARBs on endothelial function still couldn\'t be well maintained in a long span. This suggested the improvement of endothelial function and reduction of blood pressure are not paralleled, which shined a deep clinical thinking that how to well set anti-hypertensive target based on the purpose of improvement of endothelial function.

ARBs improve endothelial function {#s4b}
---------------------------------

The mechanisms by which ARBs improve endothelial dysfunction are based on their ability of inhibiting angiotensin II receptor and to increasing bradykinin. On one hand, angiotensin II, by binding to angiotensin II type 1 receptor [@pone.0090217-Watanabe1], leads to vascular constriction, endothelial cell migration, proliferation and hypertrophy and increases uptake and oxidation of LDL by endothelial cells as well as oxyradical production, thus leading to endothelial dysfunction [@pone.0090217-Bell1]. On the other hand, bradykinin, via binding to the bradykinin B2 receptor, increases production and release of NO [@pone.0090217-Barrow1], prostacyclin [@pone.0090217-OKane1] and the endothelium-derived hyperpolarizing factor [@pone.0090217-Mombouli1] to cause vasodilatation, inhibition of vascular smooth muscle cell proliferation and platelet adhesion [@pone.0090217-Linz1]. Therefore, inhibition of angiotensin II receptor and increasing bradykinin production by ARBs will result in an improvement in endothelial function.

Among the trials included in this study, variant members of this class ([Table 1](#pone-0090217-t001){ref-type="table"}) that showed benefit on endothelial function are involved, including telmisartan (40 mg [@pone.0090217-Morimoto1], 40--80 mg [@pone.0090217-Benndorf1], 160 mg [@pone.0090217-Pelliccia1]), losartan (50 mg [@pone.0090217-Trevelyan1], 50--100 mg [@pone.0090217-Chung1], 100 mg [@pone.0090217-Koh1], [@pone.0090217-Hornig1], [@pone.0090217-Yavuz1], [@pone.0090217-Flammer1]), irbesartan (150 mg [@pone.0090217-Sola1], [@pone.0090217-SouzaBarbosa1], 300 mg [@pone.0090217-Koh1], [@pone.0090217-Warnholtz1], [@pone.0090217-Sozen1]), candesartan (16 mg [@pone.0090217-Koh1], [@pone.0090217-PerroneFilardi1], [@pone.0090217-Koh2], [@pone.0090217-Koh3]) and valsartan (20 mg [@pone.0090217-Lunder1], 160 mg[@pone.0090217-Sozen1], [@pone.0090217-Yilmaz1], 160--320 mg [@pone.0090217-Rajagopalan1]), thus to confirm that the protective effect on endothelial function is the common feature of ARBs

ARBs versus ACEI {#s4c}
----------------

Recently, several studies have assessed the effect of ARBs and ACEIs on endothelial function as measured by brachial or radial FMD. As two antihypertensives in the involvement of renin angiotensin system (RAS), they have similar mechanisms. ACEIs could reduce production of angiotensin (Ang) II by inhibiting angiotensin converting enzyme, a key enzyme affecting the transformation from angiotensin I to angiotensin II [@pone.0090217-Alreja1]. Also, the inhibition of the angiotensin converting enzyme also increased bradykinin production [@pone.0090217-Pellacani1]. However, the findings of"ACE escape" phenomenon [@pone.0090217-Biollaz1] and other pathways, i.e. chymotrypsin-like enzymes that also induce Ang I to Ang II indicated ACE was not the major Ang II-forming enzyme [@pone.0090217-Urata1], [@pone.0090217-Urata2], thus directly given rise to the first member of ARBs, losartan. ARBs directly inhibited the binding between Ang II with its receptors, which seem more downstream and reliable. Consider the inhibition of Ang II is the leading mechanism of the improved endothelial function, ARB is seemed to superior to ACEIs. Since then, a wealth of clinical trial data has accumulated.

However, in this study, we pooled 8 studies that conducted ARBs and AECI monotherapy on endothelial dysfunction and found that 7 trials [@pone.0090217-Koh2], [@pone.0090217-Trevelyan1], [@pone.0090217-SouzaBarbosa1], [@pone.0090217-Hornig1], [@pone.0090217-Yavuz1], [@pone.0090217-Koh3], [@pone.0090217-Sozen1] show they can both improve FMD without significant difference but 1 trial [@pone.0090217-Ghiadoni1] showed ARBs were less effective than ACEI. That\'s difficult to explain well using current mechanisms. Besides, some trials have compared the combination of ARBs and ACEI with monotherapy. K.K. Koh 2007 [@pone.0090217-Koh3] demonstrated beneficial effects of the combination therapy superior to monotherapy with either drug and explained this by a greater extent of increased NO bioavailability. However, L.A. Souza-Barbosa [@pone.0090217-SouzaBarbosa1] found that the combined effect of the two drugs on endothelial dysfunction was not better than either of these drugs separately. Hence, for this issue, we still need further evidence.

FMD for endothelial function {#s4d}
----------------------------

For clinical assessment of endothelial function, FMD using high-resolution ultrasound to the forearm artery diameter is a well-known noninvasive method of detecting endothelial dysfunction. The mechanism is that reactive hyperemia induces increased blood flow and shear stress, stimulating NO release and vasodilation [@pone.0090217-Davignon1]. The systemic nature of atherosclerosis is reflected by the close correlation between endothelial dysfunction in the forearm and coronary endothelial dysfunction [@pone.0090217-Anderson1]. However, FMD to evaluate endothelial function also has some shortcomings. It is poor resolution relative to arterial size, highly operator-dependent and variable in measurements [@pone.0090217-Inaba1]. So it is important to note that in this meta-analysis we effect of ARBs on peripheral endothelial function base on FMD and there may be some certain variation existence.

Duration-effect relationship between ARBs and endothelial function {#s4e}
------------------------------------------------------------------

A.B.SOZEN [@pone.0090217-Sozen1] indicated ARBs (irbesartan 300 mg/day or valsartan 160 mg/day) monotherapy improved endothelial function at 6 weeks after treatment, but this benefit fell below baseline at the one and three-year measurements, while there was no worsening in blood pressure control. Furthermore, our analysis all available data about the relationship between duration of ARBs therapy and FMD change percent and found that the FMD change percent was relatively stable within the first 6 months (95% CI −0.484 to 0.360, p = 0.764) (see [Fig.4](#pone-0090217-g004){ref-type="fig"}), but felt down quickly after 6 month (95% CI−1.065 to 0.549, p = 0.154). In total, the benefit of ARBs on endothelial function wouldn\'t be well maintained (95% CI −1.990 to −0.622, p = 0.001) (see [Fig. 4](#pone-0090217-g004){ref-type="fig"}), while BP targets were well reached in all trials. These results suggested that the improvement of endothelial function and lowering BP are not paralleled. Similar finding was also supported by Panza et al. [@pone.0090217-Panza1], who found that endothelial impairment persisted after antihypertensive treatment had produced a clinical effect. Additionally, two studies [@pone.0090217-Rossing1], [@pone.0090217-Schmieder1] suggested that very high doses of ARBs may exert a significantly greater anti-proteinuric action than standard doses, with no increment in the antihypertensive effect. We hypothesized that endothelial dysfunction might be resistant or irreversible if the pathological process is established and whether gradual increasing doses of ARBs with the extending of time of treatment may help to achieve persistent amelioration of endothelial function.

Endothelial function is known to be associated with the survival in patients with cardiovascular diseases and long-term use of ARBs is also associated with the survival in patients with cardiovascular diseases. However, we found that benefits of ARBs wouldn\'t provide persistent benefit on endothelial function in a long span. How to explain this paradox? On one hand, ARBs could not just improve endothelial dysfunction but also lower hypertension, relieve vascular remodeling and atherosclerosis as well as relieve metabolic syndrome et al [@pone.0090217-Bell1]. On the other hand, this finding, benefits of ARBs on endothelial function couldn\'t be well maintained in a long span, was based on available data of 22 studies of which only 2 contributed follow-up data after 6 months [@pone.0090217-Rajagopalan1], [@pone.0090217-Sozen1], thus need further more evidence for confirmation.

Study strengths and limitations {#s4f}
-------------------------------

Our study is important in the sense that this is the first meta-analysis of the literature which assessed the effect of ARBs on endothelial function as measured by fore-arm compared to placebo or no treatment and other antihypertensive agents. The strengths of this meta-analysis include a comprehensive literature search that included RCTs only. Although, authors of 3 trials (not included and cited) were contacted as missing baseline FMD value, we received no responses and therefore excluded them reluctantly. This may cause publication bias, although both tests by Begg\'s test (P = 0.350) and the Egger\'s test (P = 0.357) provided no statistical evidence. Another limitation of this meta-analysis is the high heterogeneity among included studies. This might be explained that patients included in our meta-analysis with endothelial dysfunction caused by different diseases.

Also, there are many widely-used methods to test endothelial function, including invasive methods, such as forearm blood flow, and non-invasive methods, such as FMD. In our study, we prefer to focus on the non-invasive methods and use FMD only for endothelial function, since it is more convenient for clinical application.
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